Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CR Bard to market CorMedica's heart laser system:

This article was originally published in Clinica

Executive Summary

CR Bard is to have exclusive, worldwide distribution rights to CorMedica's systems for catheter-based, percutaneous transluminal endomyocardial revascularisation (PTER) procedures. The products treat serious coronary artery disease by delivering laser energy through a catheter to create channels in the heart muscle. CorMedica is a privately-held company based in Natick, Massachusetts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT084021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel